SCD and diabetic kidney disease: Given that SFA-mediated cellular toxicity contributes to both tubulointerstitial lesions and podocyte injury, stimulating SCD1 activity may become a novel therapeutic target for improving the renal prognosis by both reducing proteinuria and ameliorating PTEC damage in the refractory diabetic nephropathy.